GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

Summary

This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.

Timeline

Start

2006-10

Primary completion

2010-11

Completion

2010-11

Outcome

Met primary endpoint

paper Significantly more nsNSAID users met the primary endpoint PMID 23399552 ↗

registry Celecoxib vs nsNSAIDs; p = 0.0003 NCT00373685 ↗

Publications

• Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013 Mar;108(3):392-400. doi: 10.1038/ajg.2012.467. Epub 2013 Feb 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	—	—

Indications